Main Uses and Benefits of Benestan OD

Benestan OD is a medication primarily used for the management of symptoms associated with Benign Prostatic Hyperplasia (BPH), a condition characterized by the non-cancerous enlargement of the prostate gland.

Targeted Symptom Relief

The medication is designed to address Lower Urinary Tract Symptoms (LUTS) that commonly occur when an enlarged prostate puts pressure on the urethra. It helps manage several specific urinary issues, including:

• Difficulty initiating urination: Reducing the effort required to start the flow of urine.
• Weak urinary stream: Improving the force and consistency of the flow.
• Dribbling: Minimizing the occurrence of involuntary leaking at the end of urination.
• Incomplete emptying: Addressing the sensation that the bladder has not been fully cleared after use.

Improvements in Urinary Frequency

In addition to improving the mechanics of urination, Benestan OD helps manage symptoms related to bladder storage. This includes a reduction in the sudden, urgent need to urinate and a decrease in the frequency of urination throughout the day and night. By stabilizing these patterns, the medication aims to reduce the disruption to daily activities and sleep.

Mechanism of Action and Benefits

Benestan OD belongs to a class of medications known as alpha-1 adrenoceptor antagonists. It works by specifically targeting and relaxing the smooth muscles located in the prostate and the bladder neck.

The primary benefits of this action include:

• Reduced Resistance: By relaxing the muscular tissues, the medication lowers the resistance to urine flow through the urethra.
• Functional Improvement: The relaxation of the bladder neck facilitates a more efficient and comfortable voiding process.
• Quality of Life: By addressing the obstructive and irritative symptoms of BPH, the medication supports a more predictable urinary routine.

Regulatory References

1. Alfuzosin: MedlinePlus Drug Information

Eligibility: Who Can and Cannot Use Benestan OD

Eligibility for Benestan OD (Alfuzosin Extended-Release) is strictly defined by official regulatory labeling, primarily limiting its use based on gender, age, organ function, and concurrent medications. The medicine is officially indicated only for adult men for the treatment of signs and symptoms of Benign Prostatic Hyperplasia (BPH). Use in women (including during pregnancy or lactation) and pediatric patients (under 18 years) is not indicated as safety and efficacy have not been established.

Absolute Contraindications

The medicine must not be used in the following populations:

• Patients with moderate or severe hepatic impairment (liver disease).
• Patients with a known hypersensitivity to alfuzosin, to other quinazoline derivatives, or to any component of the tablet.
• Patients taking any other alpha-1 (alpha1) receptor blockers.

Conditional Use and Restrictions

Use requires caution or is not recommended in patients with severe renal impairment (Creatinine Clearance < 30 mL/min) due to limited clinical data. Older adults are permitted to use the medicine but may require special monitoring. Conditional use is also required for patients with pre-existing conditions like QT prolongation or unstable angina, as noted in prescribing information.

Interactions with other medicines and products

Benestan OD (Alfuzosin Extended-Release) has documented interaction patterns that establish specific restrictions and requirements for its administration, all based on official regulatory labeling.

Contraindicated Combinations

Co-administration is contraindicated with potent CYP3A4 inhibitors (such as Ketoconazole, Itraconazole, and Ritonavir) because these medicines significantly increase Alfuzosin plasma concentrations through pharmacokinetic inhibition. The combination with other alpha1-adrenergic receptor antagonists (alpha-blockers) is also prohibited due to the documented risk of additive hypotensive effects.

Pharmacodynamic and Exposure Interactions

Concomitant use with other antihypertensive medications, including beta-blockers, Nitrates, and Phosphodiesterase-5 (PDE5) Inhibitors, carries an increased risk of symptomatic hypotension and syncope due to combined blood pressure-lowering effects. Weak inhibitors, such as Cimetidine, are documented to cause a minor increase in Alfuzosin exposure levels.

Administration Requirements and Restrictions

Interaction Type	Requirement/Restriction	Outcome
Drug–Food	The product must be taken with food (immediately following a meal).	Administration while fasting reduces drug absorption by approximately 50%.
Population	Contraindicated in moderate or severe hepatic impairment.	Reduced clearance leads to substantially increased drug exposure.

Use of alcohol may also increase the risk of hypotensive effects.

Selective Alpha-1 Adrenoceptor Blockade

Benestan OD contains alfuzosin, which operates as a competitive antagonist by selectively binding to alpha-1 adrenergic receptors (alpha1-ARs) in targeted tissues. This interaction prevents the binding of endogenous catecholamines (such as norepinephrine) that normally activate these receptors, thereby interrupting the signaling sequence that controls smooth muscle function.

---

Modulation of Urogenital Smooth Muscle Tone

The primary pathway effect is the inhibition of smooth muscle contraction. This mechanism influences systems where alpha1-AR-mediated processes dominate, such as the lower urinary tract. The drug modifies early molecular steps that result in decreased cellular calcium influx and subsequent muscle relaxation, inducing changes consistent with decreased pathway output and reduced muscular tension.

How Benestan OD is Used: Official Administration Guidelines

Benestan OD is a prescription-only medication administered orally, and its use is guided by established administration protocols to ensure proper and consistent delivery of the active ingredient, Alfuzosin Hydrochloride.

Standard Dosing and Intake Instructions

Parameter	Official Administration Rule (10 mg Extended-Release Tablet)
Route of Administration	Oral
Standard Daily Dose	One 10 mg tablet taken once daily.
Timing with Food	Must be taken with food, specifically immediately after the same meal each day. The absorption of alfuzosin is approximately 50% lower under fasting conditions.
Preparation	Tablets must be swallowed whole. They should not be crushed, chewed, split, or powdered, as this can lead to inappropriate release of the medicine.
Missed Dose	If a dose is missed, continue with the regular schedule. Do not take two doses to make up for the missed one.

---

Use in Specific Populations

Established guidelines outline specific instructions concerning use in certain patient groups:

• Older Adults (over 65 years): The standard 10 mg once-daily dose is generally applied, as dose reduction is usually not necessary based on clinical and pharmacokinetic data.
• Hepatic Impairment: Use is contraindicated (must not be used) in patients with moderate or severe liver impairment.
• Renal Impairment: Caution should be exercised when the medicine is administered to patients with severe kidney impairment (creatinine clearance < 30 mL/min).
• Pediatric Population: Benestan OD is not indicated or recommended for use in the pediatric population.

Research evidence / Overview of studies for Benestan OD

Evidence from Trials for Symptoms of Benign Prostatic Hyperplasia (BPH)

The primary clinical research that evaluated Benestan OD (Alfuzosin Extended-Release) consists of short-term, double-blind Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time when comparing the medicine against a placebo (an inactive substance) in adult men diagnosed with moderate to severe Lower Urinary Tract Symptoms (LUTS) linked to Benign Prostatic Hyperplasia (BPH).

Researchers monitored the change in the International Prostate Symptom Score (IPSS), a patient-reported measure assessing symptom severity, and the physical measurement of Peak Urinary Flow Rate (Q max). Findings describe patterns observed in these studies, where researchers documented changes in both symptom scores and functional flow measurements. The evidence derived from these studies informs understanding of short-term symptom patterns.

Research on Long-Term Outcomes and Disease Progression

Longer-term research explored outcomes beyond the initial three months to examine the persistence of the changes measured. This research involved both controlled trials and open-label extension studies, with some studies observing responses over defined time intervals up to three years.

Studies also monitored hard clinical endpoints related to disease progression, such as the first occurrence of Acute Urinary Retention (AUR) and the need for BPH-related surgical intervention. Open-label study data describe patterns related to the consistency of the symptom and flow measures for periods up to one year. However, the certainty remains low regarding the effect on the specific individual endpoint of AUR, as evidence was observed in some studies but findings were mixed when analyzed separately.

Studies in Specific Populations

Research populations in the core clinical trials consisted mostly of adult men with symptomatic BPH. The core research was evaluated in adult men (typically 50 years and older), and studies included a substantial portion of older men (aged 65 and older). Subgroup analyses described patterns on how symptoms evolved in men who were concurrently receiving certain antihypertensive medications.

Gaps and Areas of Research Uncertainty

The primary limitation is that follow-up durations were limited in the pivotal RCTs, which only explored short-term symptom changes. Consequently, long-term effects are not fully established by these controlled studies. Many long-term assessments transitioned into open-label designs, which are not as rigorous as blinded trials, meaning evidence quality varies across studies regarding sustained effects. Furthermore, comparative evidence against alternative standard treatments for BPH is lacking in the primary clinical trial data submitted for regulatory review.

Common questions about Benestan OD (FAQ)

Q: How long does it take for Benestan OD to start working to relieve BPH symptoms?

A: Regulatory clinical studies monitored changes in Benign Prostatic Hyperplasia (BPH) symptoms over time, with major assessments often taking place after approximately three months of treatment. Some official product summaries report that the time to reach peak blood concentration, which drives the drug's effect on smooth muscle, can be within a few days of starting treatment.

---

Q: Is Benestan OD safe for women and children?

A: According to official regulatory documents, Benestan OD is not indicated for use in women or in the pediatric population (children). This is because the safety and effectiveness of the medicine have not been established in these specific groups. The medicine is indicated solely for the treatment of BPH signs and symptoms in adult men.

---

Q: How does Benestan OD interact with alcohol?

A: Official product information includes a warning that consuming alcohol while taking this medicine may increase the risk of hypotensive effects. These effects refer to a drop in blood pressure that may lead to symptoms such as dizziness or feeling faint. The warning is based on this documented risk.

---

Q: Is it possible to take Benestan OD every other day?

A: Official prescribing information establishes the recommended dosage as one 10 mg extended-release tablet taken once daily. Regulatory documents do not provide information on or support an alternative every-other-day dosing regimen for this medication.

---

Q: Is Benestan OD used to treat any other conditions besides BPH?

A: Official product labeling indicates that this medicine is approved solely for the treatment of the signs and symptoms of Benign Prostatic Hyperplasia (BPH) in adult men. It is not indicated for the treatment of high blood pressure (hypertension) or any other medical conditions.

---

Q: What is IFIS (Intraoperative Floppy Iris Syndrome) and what is its relevance to Benestan OD?

A: Intraoperative Floppy Iris Syndrome (IFIS) is a complication reported during cataract surgery in some patients who are currently taking or have previously taken alpha-blockers like Benestan OD. Official safety warnings advise that IFIS is a variant of small pupil syndrome. This information is relevant to patients undergoing cataract surgery, and healthcare providers need to be aware of prior or current use of this medication.

Storage and Disposal Requirements

Official regulatory documents define strict conditions for the storage, handling, and disposal of this medicine, which is commonly associated with belimumab.

Mandatory Storage Conditions

• Temperature: The unopened product must be stored in a refrigerator, protected from freezing, typically between 2 C to 8 C (36 F to 46 F).
• Protection: Keep the product in the original carton to protect it from direct sunlight and avoid vigorous shaking.
• Child Safety: Store the medicine out of the reach of children.

Stability and Handling

After reconstitution (IV form) or removal from refrigeration (SC form), the product has a strictly limited period before it must be administered or discarded, such as an 8-hour total limit for the IV infusion. The product must be visually inspected before use, and should not be used if it appears cloudy, discolored, or contains particles.

Disposal of Used Medicine

All used injection devices, such as autoinjectors and syringes, must be placed immediately into a puncture-resistant, FDA-cleared sharps disposal container. This container must not be thrown in household trash or recycled. Any unused or expired medicine must be disposed of according to a healthcare provider's instructions and local regulatory requirements.